Florence Ida Hsu, MD
Assistant Professor of Medicine (Rheumatology, Allergy & Immunology)Cards
Additional Titles
Training Program Director - Allergy & Immunology Fellowship, Internal Medicine
Contact Info
Allergy & Immunology
333 Cedar Street, PO Box 208013
New Haven, CT 06520-8013
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Training Program Director - Allergy & Immunology Fellowship, Internal Medicine
Contact Info
Allergy & Immunology
333 Cedar Street, PO Box 208013
New Haven, CT 06520-8013
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Training Program Director - Allergy & Immunology Fellowship, Internal Medicine
Contact Info
Allergy & Immunology
333 Cedar Street, PO Box 208013
New Haven, CT 06520-8013
United States
About
Titles
Assistant Professor of Medicine (Rheumatology, Allergy & Immunology)
Training Program Director - Allergy & Immunology Fellowship, Internal Medicine
Biography
F. Ida Hsu, MD, is an allergist and immunologist who treats a wide range of conditions and illnesses, including asthma, allergic rhinitis, drug hypersensitivity and hives with unknown cause. “I often approach cases as a detective would, looking for clues to an answer—sometimes obvious, and sometimes elusive,” she says. “Having suffered from hives and various allergies when I was younger, I can relate to my patients and provide practical advice.”
An assistant professor of clinical medicine at Yale School of Medicine, Dr. Hsu studied medicine at Columbia University's College of Physicians & Surgeons, trained in Internal Medicine at New York Presbyterian Hospital-Weill Cornell Medical Center, and completed her Allergy and Immunology fellowship at the Brigham & Women's Hospital in Boston, MA, where she served on the clinical faculty for several years before coming to Yale.
Over the years, she has been involved in clinical trials focused on finding new treatments for hereditary angioedema, a rare genetic disorder that causes swelling in the face, upper air passageways and other parts of the body. She also provides specialized care for patients with chronic rhinosinusitis, nasal polyposis, and aspirin-exacerbated respiratory disease, in collaboration with Yale and other community otolaryngologists and pulmonary physicians.
When meeting a new patient, Dr. Hsu says, “First step first: let’s do some testing, figure out what we’re dealing with, and then we can come up with a plan to address your symptoms and get you feeling better.” Sometimes testing is not required, and she is able to make recommendations for medications or non-pharmacologic treatments to help her patients with their allergy or immunology issues.
Appointments
Allergy & Immunology
Assistant ProfessorPrimary
Other Departments & Organizations
Education & Training
- Fellow
- Brigham & Women's Hospital, Boston, MA (2006)
- Resident
- NewYork-Presbyterian/Weill Cornell Medical Center, New York, NY (2003)
- Intern
- NewYork-Presbyterian/Weill Cornell Medical Center, New York, NY (2001)
- MD
- Columbia University Coll of Physicians & Surgeons (2000)
- BA
- Harvard University, Biology (1994)
Research
Overview
Medical Research Interests
ORCID
0000-0003-2201-9442
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Junghee Jenny Shin, MD, PhD
Jason Kwah, MD, MSc
Jennefer Par-Young
Ami Belmont, MD
Craig B. Wilen, MD, PhD
Geoffrey Chupp, MD
Drug Hypersensitivity
Asthma
Publications
2024
BEING ATTACK-FREE WITH GARADACIMAB IMPROVES QUALITY OF LIFE IN PATIENTS WITH HEREDITARY ANGIOEDEMA
Hsu F, Lumry W, Aygoren-Pursun E, Braverman J, Lawo J, Pollen M, Nenci C, Craig T. BEING ATTACK-FREE WITH GARADACIMAB IMPROVES QUALITY OF LIFE IN PATIENTS WITH HEREDITARY ANGIOEDEMA. Annals Of Allergy Asthma & Immunology 2024, 133: s33-s34. DOI: 10.1016/j.anai.2024.08.129.Peer-Reviewed Original ResearchConceptsOpen-label extensionAttack-free patientsHereditary angioedemaHRQoL improvementAttack-freeImpaired health-related quality of lifeHealth-related quality of lifeAE-QoLClinically meaningful HRQoL improvementAssociated with HRQoL improvementsExposure cohortPhase 3 studySustained HRQoL improvementQuality of lifePost hoc analysisHRQoL outcomesScore reductionHRQoLPatientsHoc analysisCohortTreatment goalsImpairment scoresAngioedemaDisease controlCHARACTERIZATION OF INJECTION SITE-RELATED ADVERSE EVENTS WITH GARADACIMAB IN PATIENTS WITH HEREDITARY ANGIOEDEMA
Jacobs J, Manning M, Reshef A, Yamagami K, Shetty H, Lawo J, Pollen M, Hsu F. CHARACTERIZATION OF INJECTION SITE-RELATED ADVERSE EVENTS WITH GARADACIMAB IN PATIENTS WITH HEREDITARY ANGIOEDEMA. Annals Of Allergy Asthma & Immunology 2024, 133: s30-s31. DOI: 10.1016/j.anai.2024.08.121.Peer-Reviewed Original ResearchConceptsInjection-site reactionsLong-term prophylaxisHereditary angioedemaReduce treatment burdenIncidence of injection-site reactionsInjection-site adverse eventsPhase 3 clinical programTreatment burdenInjection site-relatedPlacebo-receiving patientsPhase 3 studyStudy treatment groupsFavorable safety profileLife-threatening attacksTotal disease controlOnce-monthlySafety profileAdverse eventsPhase 3Clinical studiesPatient proportionErythemaPatientsMonoclonal antibodiesPruritusACQUIRED ANGIOEDEMA: THE GREAT IMITATOR
Mathew M, Liao J, Zidan E, Hsu F, Belmont A. ACQUIRED ANGIOEDEMA: THE GREAT IMITATOR. Annals Of Allergy Asthma & Immunology 2024, 133: s136. DOI: 10.1016/j.anai.2024.08.560.Peer-Reviewed Original ResearchConceptsAAE-C1-INHEmergency departmentAcquired angioedema due to C1-inhibitor deficiencyAngioedema due to C1-inhibitor deficiencySplenic marginal zone lymphomaAssociated with lymphoproliferative disordersFatal laryngeal edemaMarginal zone lymphomaC1 inhibitor deficiencyLocal anesthetic allergyBradykinin-mediated angioedemaDelayed onset symptomsDrug allergy testingDuration of swellingRecombinant C1 inhibitorInitial rituximabEyelid swellingInhibitor deficiencyLow C4Lymphoproliferative disordersDental proceduresAbortive therapyRecurrent episodesRare conditionLaryngeal edema
2023
PLCG2-associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations related to functional classes of genetic variants
Baysac K, Sun G, Nakano H, Schmitz E, Cruz A, Fisher C, Bailey A, Group P, Abbott J, Becerra J, Allenspach E, Assing K, Atkinson T, Bargir U, Baxter S, Bergerson J, Bista R, Blanche S, Buckley L, Butte M, Carcamo B, Chandrakala S, Chen K, Chervinskiy S, Chinn I, Chong H, Coffey K, Copland A, Cowen E, Cros G, De Bruycker J, de la Morena M, Ehlayel M, Satter L, Gelfand E, Gilliaux O, Glover S, Gorman M, Griffin T, Grimbacher B, Gru A, Haddad E, Hadjadj J, Hajjar J, Hauck F, Hautala T, Holland S, Hsieh E, Hsu F, Jacquemin E, Jindal A, Kahn S, Keller M, Kobayashi R, Krupski C, Larkin A, Lawrence M, Madkaikar M, Malphettes M, Martelius, Mehta M, Metcalfe D, Meyts I, Nannapaneni N, Vinyals J, Olivier K, Ombrello A, Orange J, Rabinovitch N, Rauscher C, Redfern A, Reynolds P, Rieux-Laucat F, Secord E, Seeborg F, Seppänen M, Sereti I, Shin D, Shin J, Snapper S, Suri D, Tangcheewinsirikul S, Thatayatikom A, Torgerson T, Touzot F, Uzel G, Varjosalo M, Vasconcelos D, von Bernuth H, Walsh T, Walter J, Ward B, Wittkowski H, Wysocki C, Mace E, Milner J, Ombrello M. PLCG2-associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations related to functional classes of genetic variants. Journal Of Allergy And Clinical Immunology 2023, 153: 230-242. PMID: 37769878, PMCID: PMC11337301, DOI: 10.1016/j.jaci.2023.08.036.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsImmune dysregulationPhospholipase C gamma 2Gain of functionB cellsNatural killer cell dysfunctionCalcium fluxLoF variantsNatural killer cellsHumoral immune deficiencyDistinct clinical presentationsPrimary patient cellsExtracellular signal-regulated kinase (ERK) phosphorylationB cell activationSignal-regulated kinase phosphorylationPLCG2 mutationsAntibody deficiencyKiller cellsClinical presentationImmune deficiencyCell dysfunctionClinical dataStandardized questionnaireFunctional alterationsSporadic casesPathogenic variantsA safe, effective, and single-day protocol for rapid drug desensitization to intravenous iron dextran
Belmont A, Liao J, Hsu F, Kwah J. A safe, effective, and single-day protocol for rapid drug desensitization to intravenous iron dextran. The Journal Of Allergy And Clinical Immunology In Practice 2023, 11: 3242-3244.e1. PMID: 37329952, DOI: 10.1016/j.jaip.2023.06.018.Peer-Reviewed Original Research
2022
Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age
Hsu FI, Lumry W, Riedl M, Tachdjian R. Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age. Allergy, Asthma & Clinical Immunology 2022, 18: 64. PMID: 35831891, PMCID: PMC9281160, DOI: 10.1186/s13223-022-00689-9.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHereditary angioedemaHealth statusAdverse fetal outcomesCohort of patientsChoice of therapyContinuity of careMedical Advisory BoardC1-INH deficiencyWomen's health statusRisk-benefit assessmentHAE attacksHAE managementFetal outcomesProphylactic therapyPatient populationTreatment optionsFemale sexDisease burdenTreatment decisionsContraceptive useUnpredictable episodesTreatment efficacyMucous membranesGynecologic specialistsPregnancyDefining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency
Shin JJ, Par-Young J, Unlu S, McNamara A, Park HJ, Shin MS, Gee RJ, Doyle H, Afinogenova Y, Zidan E, Kwah J, Russo A, Mamula M, Hsu FI, Catanzaro J, Racke M, Bucala R, Wilen C, Kang I. Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency. Journal Of Clinical Immunology 2022, 42: 1137-1150. PMID: 35713752, PMCID: PMC9203263, DOI: 10.1007/s10875-022-01296-4.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsMeSH KeywordsAntibodies, ViralCD8-Positive T-LymphocytesCommon Variable ImmunodeficiencyCOVID-19COVID-19 VaccinesHumansImmunity, CellularImmunoglobulin AImmunoglobulin GMRNA VaccinesPrimary Immunodeficiency DiseasesRNA, MessengerSARS-CoV-2Spike Glycoprotein, CoronavirusVaccinationVaccinesVaccines, SyntheticConceptsCommon variable immune deficiencyT cellsImmune responseIgG responsesCVID patientsMRNA vaccinesB cellsCoronavirus disease 2019 (COVID-19) mRNA vaccinesCOVID-19 mRNA vaccinesBaseline immune profileHistory of autoimmunityPrimary antibody deficiencyT cell responsesCellular immune responsesPoor immune responseVariable immune deficiencyMemory B cellsSARS-CoV-2 spike proteinBaseline IgGCVID diagnosisEM CD8Immunological predictorsPAD cohortSpecific CD4Immune profileClinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor
Jones DH, Bansal P, Bernstein JA, Fatteh S, Harper J, Hsu FI, O’Connor M, Park N, Suez D. Clinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor. World Allergy Organization Journal 2022, 15: 100621. PMID: 35145604, PMCID: PMC8804245, DOI: 10.1016/j.waojou.2021.100621.Peer-Reviewed Original ResearchConceptsManagement of HAEMost patientsHereditary angioedemaC1 esterase inhibitorAngioedema attacksHAE attacksMedian ageClinical profileSerum levelsRhC1-INHTreatment outcomesRecombinant human C1 esterase inhibitorNormal C1 esterase inhibitorEsterase inhibitorHuman C1 esterase inhibitorAcute HAE attacksHigh-dose antihistaminesUS treatment centersPatient-reported assessmentsLow serum levelsPatient-reported outcomesC1-INH deficiencyAvailability of treatmentImproved disease controlBreakthrough attacks
2021
Low IgG trough and lymphocyte subset counts are associated with hospitalization for COVID-19 in patients with primary antibody deficiency
Kuster JK, Unlu S, Makin TA, Par-Young J, Simonov M, Shafi S, Balanda M, Randolph C, Steele R, Hsu FI, Price C, Kohli-Pamnani A, Borish L, Lawrence MG, Kang I, Shin JJ. Low IgG trough and lymphocyte subset counts are associated with hospitalization for COVID-19 in patients with primary antibody deficiency. The Journal Of Allergy And Clinical Immunology In Practice 2021, 10: 633-636.e3. PMID: 34929372, PMCID: PMC8683251, DOI: 10.1016/j.jaip.2021.11.030.Peer-Reviewed Original Research
2020
Clinical presentation of hereditary angioedema.
Azmy V, Brooks JP, Hsu FI. Clinical presentation of hereditary angioedema. Allergy & Asthma Proceedings 2020, 41: s18-s21. PMID: 33109320, DOI: 10.2500/aap.2020.41.200065.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH Keywords and ConceptsConceptsHereditary angioedemaHAE attacksSevere abdominal painHalf of patientsAutosomal dominant diseaseC1 inhibitor proteinLaryngeal angioedemaOropharyngeal swellingAbdominal attacksAbdominal painErythema marginatumSignificant hypotensionLaryngeal edemaPrompt diagnosisClinical presentationMinor traumaSignificant morbiditySubmucosal edemaBowel soundsPhysical examinationRecurrent episodesGenitourinary tractFrequent precipitantUnpredictable severityVariable presentation
Academic Achievements & Community Involvement
activity Data Safety Monitoring Committee for Protocol ITL-2002-CL-001 entitled “Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults with Hereditary Angioedema (HAE)
Advisory BoardsCommittee MemberDetailsIntellia Pharmaceuticals01/28/2023 - Presentactivity Virtual Medical Advisory Board
Advisory BoardsBoard MemberDetailsBiocryst Pharmaceuticals03/02/2021 - Presentactivity Systemic Mastocytosis Advisory Board
Advisory BoardsBoard MemberDetailsBlueprint Medicines07/17/2020 - Presentactivity HAE Virtual Advisory Board,
Advisory BoardsBoard MemberDetailsTakeda Pharmaceutical Company07/25/2020 - Presentactivity Advances in Hereditary Angioedema (HAE) Prophylaxis Advisory Board
Advisory BoardsBoard MemberDetailsBiocryst Pharmaceuticals06/22/2019 - Present
Clinical Care
Overview
F. Ida Hsu, MD, is an allergist and immunologist who treats a wide range of conditions and illnesses, including asthma, allergic rhinitis, food allergies, drug hypersensitivity and hives with unknown cause. “I often approach cases as a detective would, looking for clues to an answer—sometimes obvious, and sometimes elusive,” she says. “Having suffered from hives and various allergies when I was younger, I can relate to my patients and provide practical advice.”
An assistant professor of clinical medicine at Yale School of Medicine, Dr. Hsu has also been involved in clinical trials focused on finding new treatments for hereditary angioedema, a rare genetic disorder that causes swelling in the face, upper air passageways and other parts of the body. She also provides specialized care for patients with nasal polyposis and aspirin-exacerbated respiratory disease, in collaboration with Yale and other community otolaryngologists.
When meeting a new patient, Dr. Hsu says, “First step first: let’s do some testing, figure out what we’re dealing with, and then we can come up with a plan to address your symptoms and get you feeling better.” Sometimes testing is not required, and she is able to make recommendations for medications or non-pharmacologic treatments to help her patients with their allergy or immunology issues.
Clinical Specialties
Fact Sheets
Seasonal Allergies (Allergic Rhinitis)
Learn More on Yale MedicineMultisystem Inflammatory Syndrome in Children (MIS-C)
Learn More on Yale MedicinePediatric Cancer Immunotherapy
Learn More on Yale MedicineColds: How to Prevent Them
Learn More on Yale Medicine
Board Certifications
Allergy & Immunology
- Certification Organization
- AB of Allergy & Immunology
- Original Certification Date
- 2005
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- February 23, 2024
Department of Internal Medicine Promotions and Appointments (February 2024)
- March 06, 2023Source: CT Insider
Connecticut is in for a longer, more severe allergy season. Here's why.
- August 11, 2022
Discoveries & Impact (August 2022)
- March 17, 2022
Discoveries & Impact (March 2022)
Get In Touch
Contacts
Allergy & Immunology
333 Cedar Street, PO Box 208013
New Haven, CT 06520-8013
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.